de Gaetano G, Cerletti C
Centro di Ricerche e Formazione ad Alta Tecnologia nelle Scienze Biomediche, Università Cattolica, Campobasso, Italy.
Nutr Metab Cardiovasc Dis. 2001 Aug;11(4 Suppl):47-50.
The objective of the European project FAIR CT 97 3261 "Wine & Cardiovascular Disease" was to have insight into the biological effects and mechanisms of wine constituents as protective factors against cardiovascular disease and to evaluate their clinical relevance in the context of a regular and moderate wine consumption (1, 2). The project aimed at evaluating the effects of red wine polyphenolic extracts (RWPE) on the major components contributing to the pathophysiology of atherosclerosis and thrombosis, namely vascular tone, haemostatic system, oxidative processes, and plaque development, in selected in vitro, ex vivo, and in vivo models (3-6). Evidence was obtained that RWPE might improve vascular function mainly through nitric oxide (NO)-mediated mechanisms, interfere with haemostatic and oxidative processes involved in the progression of vascular damage, and modulate early events of atherosclerosis. These effects were studied on cellular and plasmatic blood components and on vascular function in experimental animal models. A study in 40 healthy volunteers, performed in Barcelona, showed a significant increase in HDL cholesterol (HDL-C) levels and a decreased oxidation of LDL after red wine ingestion (30 g alcohol daily for 4 weeks) as compared to the same amount of alcohol given as spirit. A significant fall was seen, after red wine, in the expression of several markers of cardiovascular risk measured on circulating cell surface or in plasma of volunteers. Finally, a meta-analysis of all available epidemiological studies indicated a significant negative association of moderate wine consumption (150-300 ml daily) with the risk of major cardiovascular events. In conclusion, this FAIR project contributed to the establishment of a biological plausibility to the epidemiological association of moderate wine consumption with prevention of cardiovascular disease. Red wine and RWPE altogether may prove to be beneficial against the major killer of European citizens.
欧洲项目“FAIR CT 97 3261:葡萄酒与心血管疾病”的目标是深入了解葡萄酒成分作为心血管疾病保护因素的生物学效应和机制,并在规律适量饮用葡萄酒(1,2)的背景下评估其临床相关性。该项目旨在评估红酒多酚提取物(RWPE)对动脉粥样硬化和血栓形成病理生理学的主要促成成分,即血管张力、止血系统、氧化过程和斑块形成,在选定的体外、离体和体内模型中的影响(3 - 6)。有证据表明,RWPE可能主要通过一氧化氮(NO)介导的机制改善血管功能,干扰血管损伤进展中涉及的止血和氧化过程,并调节动脉粥样硬化的早期事件。这些效应在实验动物模型的细胞和血浆成分以及血管功能上进行了研究。在巴塞罗那对40名健康志愿者进行的一项研究表明,与饮用等量酒精的烈酒相比,饮用红酒(每天30克酒精,持续4周)后,高密度脂蛋白胆固醇(HDL - C)水平显著升高,低密度脂蛋白氧化减少。饮用红酒后,在志愿者循环细胞表面或血浆中测量的几种心血管风险标志物的表达显著下降。最后,对所有现有流行病学研究的荟萃分析表明,适量饮用葡萄酒(每天150 - 300毫升)与主要心血管事件风险之间存在显著的负相关。总之,这个FAIR项目为适量饮用葡萄酒与预防心血管疾病的流行病学关联建立了生物学合理性。红酒和RWPE可能共同被证明对欧洲公民的主要杀手有益。